Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Minisiston (SH D00342A)
Minisiston · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Minisiston (SH D00342A) | DRUG | Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval |
Inclusion Criteria: * Healthy women requiring contraception Exclusion Criteria: * Pregnant or lactating women, history or suspicion of hormone dependent tumor or any other conditions which forbid the participation.
Minisiston is a low dose combined oral contraceptive used for contraception in women. It is being developed by Bayer AG and has been studied in a Phase 3 Pearl Index trial in Germany. The study enrolled 840 healthy female volunteers aged 18 years and older.
Minisiston is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor behind the clinical development program for this low dose combined oral contraceptive, including the Phase 3 Pearl Index study conducted in Germany.
Minisiston is in Phase 3 clinical development. One Phase 3 trial has been completed, and no active trials are currently listed. The completed study was an uncontrolled Pearl Index study of the low dose combined oral contraceptive, with no randomized or double-blind design.
Minisiston has been evaluated in one completed Phase 3 trial, NCT00220324, titled Pearl Index Study With Low Dose Combined Oral Contraceptive. The study enrolled 840 healthy female volunteers aged 18 years and older in Germany and assessed contraception.
Yes, Minisiston is also known as Minisiston (SH D00342A). Both names refer to the same low dose combined oral contraceptive developed by Bayer AG for contraception, studied in the completed Phase 3 Pearl Index trial NCT00220324.